Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the latest clinical data and best practices regarding treatment strategies for treatment-naive patients with chronic hepatitis B infection
- Discuss differences between FDA-approved treatments for chronic hepatitis B infection
- Discuss the impact of HBeAg status on selection of most appropriate therapy for patients with chronic hepatitis B infection
Topics covered include:
- HBV Treatment Goals
- Initial Patient Evaluation and Eligibility
- Current Guideline Recommendations on What to Start
- Selection of Type of Initial HBV Therapy: Interferon vs Nucleos(t)ide Analogue Treatment
- Factors Affecting Decision Making Regarding Interferon-Based HBV Therapy
- Factors Affecting Decision Making Regarding Oral Antiviral Agents
- Antiviral Activity and Clinical Endpoints With Nucleos(t)ides
- Barrier to Resistance and On-Treatment Virologic Durability of Nucleos(t)ides
- Serologic Endpoint Rates and Off-Treatment Durability of Nucleos(t)ides
- Safety and Tolerability of Nucleos(t)ides in HBV Treatment
- Other Considerations When Initiating First-line HBV Treatment
Abstract